Sakar Healthcare Ltd

Sakar Healthcare Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Sakar Healthcare Ltd

₹ 369 2.42%
24 Apr 4:11 p.m.
Company website NSE : SAKAR
About

Sakar Healthcare Ltd is engaged in manufacturing of Pharmaceutical formulations in the form of liquid injectables, tablets/ capsules, oral liquid syrups, dry powder injectables and syrups.[1]
The company also operates as a contract development and manufacturing organization (CDMO) for various leading pharmaceutical companies.[2]

Key Points

Product Portfolio
The company manufactures various pharma products like injectables, tablets/ capsules, oral liquid syrups, dry power injections, syrups, etc. for various therapeutic segments like antibiotics, anti-cold drugs, anti-malarial, multi-vitamins, amino acids, etc.[1]
It is involved in manufacturing and marketing of medicines with a product portfolio of ~150 formulations in more than 23 therapeutic areas.[2]

Website NSE
  • Market Cap ₹ 802 Cr.
  • Current Price ₹ 369
  • High / Low ₹ 479 / 210
  • Stock P/E 64.2
  • Book Value ₹ 109
  • Dividend Yield 0.00 %
  • ROCE 8.91 %
  • ROE 8.49 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company's median sales growth is 18.0% of last 10 years

Cons

  • Stock is trading at 3.38 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Promoter holding has decreased over last quarter: -1.00%
  • Company has a low return on equity of 11.0% over last 3 years.
  • Company might be capitalizing the interest cost
  • Debtor days have increased from 49.5 to 60.4 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
26.79 21.68 30.26 31.64 29.74 36.59 28.53 30.71 33.47 40.65 38.99 34.08 37.23
22.93 14.61 23.77 24.55 23.09 27.41 20.57 22.12 24.67 32.87 29.96 24.72 28.22
Operating Profit 3.86 7.07 6.49 7.09 6.65 9.18 7.96 8.59 8.80 7.78 9.03 9.36 9.01
OPM % 14.41% 32.61% 21.45% 22.41% 22.36% 25.09% 27.90% 27.97% 26.29% 19.14% 23.16% 27.46% 24.20%
0.27 0.41 0.27 0.75 0.27 0.88 0.41 0.60 1.85 1.81 1.52 0.66 0.23
Interest 0.80 0.43 0.49 0.79 0.94 0.68 0.86 0.99 1.94 2.15 2.08 1.65 1.79
Depreciation 1.08 4.82 2.18 1.68 2.62 3.19 3.57 3.77 4.10 3.55 4.52 4.22 4.44
Profit before tax 2.25 2.23 4.09 5.37 3.36 6.19 3.94 4.43 4.61 3.89 3.95 4.15 3.01
Tax % 20.44% 22.42% 10.51% 54.19% 96.43% -45.56% 26.90% 56.21% 13.02% -0.77% 28.10% 12.53% 30.90%
1.80 1.74 3.65 2.46 0.11 9.01 2.88 1.94 4.01 3.92 2.84 3.64 2.07
EPS in Rs 1.20 1.11 2.13 1.44 0.06 5.26 1.68 1.04 2.15 2.06 1.49 1.70 0.95
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
16 22 30 35 41 44 53 68 83 95 128 133 151
9 14 22 27 33 34 40 51 63 72 99 100 116
Operating Profit 7 8 8 8 8 10 13 17 20 23 29 33 35
OPM % 43% 34% 26% 22% 20% 23% 24% 25% 24% 24% 23% 25% 23%
0 0 0 0 0 1 0 1 2 1 2 4 4
Interest 4 4 4 3 3 3 3 2 2 2 3 6 8
Depreciation 2 2 2 2 3 3 4 6 7 8 10 15 17
Profit before tax 1 2 2 2 3 5 6 9 12 13 19 17 15
Tax % 32% 19% 13% 24% 22% 30% 38% 28% 21% 19% 20% 24%
1 1 2 2 2 3 4 7 10 11 15 13 12
EPS in Rs 1.24 1.81 2.19 2.30 2.78 3.08 3.12 4.47 6.43 6.84 8.90 6.70 6.20
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 20%
5 Years: 20%
3 Years: 17%
TTM: 17%
Compounded Profit Growth
10 Years: 24%
5 Years: 27%
3 Years: 10%
TTM: -30%
Stock Price CAGR
10 Years: %
5 Years: 42%
3 Years: 47%
1 Year: 72%
Return on Equity
10 Years: 11%
5 Years: 11%
3 Years: 11%
Last Year: 8%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 8 8 8 8 8 11 12 15 15 16 17 19 21
Reserves 3 4 6 7 11 25 35 57 66 83 110 154 216
32 27 24 25 22 24 11 11 17 43 93 119 68
8 11 14 11 10 11 23 15 17 37 47 44 52
Total Liabilities 51 50 52 50 51 71 81 97 115 178 268 336 357
37 37 38 36 37 49 53 64 66 69 205 267 275
CWIP 0 0 0 0 0 0 0 9 13 49 1 6 8
Investments 0 0 0 0 0 0 0 0 0 0 7 3 0
14 13 14 14 14 22 28 25 36 60 55 60 75
Total Assets 51 50 52 50 51 71 81 97 115 178 268 336 357

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
11 7 9 4 9 2 5 16 19 15 36 33
-4 -3 -3 -1 -4 -14 -8 -25 -22 -47 -90 -74
-4 -7 -6 -3 -6 13 -13 9 3 32 55 41
Net Cash Flow 3 -4 -0 1 -1 0 -16 0 -0 -0 -0 0

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 25 22 28 21 26 44 74 51 36 48 40 60
Inventory Days 398 281 190 142 107 114 51 70 92 112 69 76
Days Payable 118 109 97 20 66 51 57 41 46 141 149 129
Cash Conversion Cycle 305 194 120 143 67 107 68 80 83 19 -39 7
Working Capital Days 194 155 75 89 45 110 108 46 41 8 2 30
ROCE % 12% 14% 15% 14% 14% 15% 15% 16% 16% 13% 12% 9%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
67.54% 67.54% 67.54% 67.54% 67.54% 62.10% 62.10% 60.72% 60.72% 54.15% 53.15% 53.15%
0.00% 0.00% 0.00% 0.00% 0.00% 16.12% 16.12% 15.74% 15.74% 14.03% 13.76% 13.52%
8.76% 8.76% 8.76% 8.76% 8.76% 0.55% 0.33% 0.00% 0.00% 10.82% 10.62% 10.62%
23.70% 23.70% 23.70% 23.70% 23.70% 21.24% 21.45% 23.54% 23.54% 21.00% 22.47% 22.71%
No. of Shareholders 4,6046,4816,5426,7026,0915,6786,2106,3226,0567,2997,0017,386

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings